Non-interventional study observing the use of Removab for the treatment of patients with malignant ascites due to EpCAM-positive carcinomas

Non-interventional study observing the use of Removab for the treatment of patients with malignant ascites due to EpCAM-positive carcinomas - CARMA

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00000458

Enrollment

150

Registered

2010-07-21

Start date

2010-06-11

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

malignant ascites

Interventions

Group 1: Treatment with Removab according to SmPC

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Patienten mit malignem Aszites, die erstmalig mit Removab gemäß Fachinformation behandelt werden. Patients with malignant ascites, who receive the first Removab treatment according to SmPC.

Exclusion criteria

Exclusion criteria: According to a non-interventional study, no study-related invetigatrions are required. Patients with malignant ascites, who receive the first Removab treatment accoridng to SmPC.

Design outcomes

Primary

Measure	Time frame
Puncture-free interval after the last Removab infusion Quality of life of patients in terms of ascites-symptoms	—

Secondary

Measure	Time frame
Verification of safety under routine conditions, characterization of patient population with regards to primary tumor and previous anti-cancer therapies, survival in post-study phase	—

Countries

Austria, Germany

Contacts

Public ContactHilke Friccius-Quecke

Fresenius-Biotech GmbH

hilke.friccius@fresenius-biotech.com089-306593-44

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026